Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Combined use of genetic polymorphisms and elastographic techniques in NAFLD. Fact or fiction?

Lombardi R, Fargion S, Fracanzani AL.

Curr Pharm Des. 2019 Nov 21. doi: 10.2174/1381612825666191122101021. [Epub ahead of print]

PMID:
31755380
2.

Impact of natural Neuromedin-B receptor variants on iron metabolism.

Rametta R, Dongiovanni P, Baselli GA, Pelusi S, Meroni M, Fracanzani AL, Busti F, Castagna A, Scarlini S, Corradini E, Pietrangelo A, Girelli D, Fargion S, Valenti L.

Am J Hematol. 2019 Nov 14. doi: 10.1002/ajh.25679. [Epub ahead of print]

PMID:
31724192
3.

Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.

Lombardi R, Airaghi L, Targher G, Serviddio G, Maffi G, Mantovani A, Maffeis C, Colecchia A, Villani R, Rinaldi L, Orsi E, Pisano G, Adinolfi LE, Fargion S, Fracanzani AL.

Liver Int. 2019 Oct 14. doi: 10.1111/liv.14274. [Epub ahead of print]

PMID:
31612634
4.

High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results.

Pisano G, Donato MF, Consonni D, Oberti G, Borroni V, Lombardi R, Invernizzi F, Bertelli C, Caccamo L, Porzio M, Dondossola D, Rossi G, Fargion S, Fracanzani AL.

Dig Liver Dis. 2019 Sep 11. pii: S1590-8658(19)30709-1. doi: 10.1016/j.dld.2019.07.007. [Epub ahead of print]

PMID:
31521545
5.

Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.

Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Dec;1864(12):158523. doi: 10.1016/j.bbalip.2019.158523. Epub 2019 Sep 7.

PMID:
31505261
6.

Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis.

Sigon G, D'Ambrosio R, Clerici M, Pisano G, Chantarangkul V, Sollazzi R, Lombardi R, Peyvandi F, Lampertico P, Fargion S, Tripodi A, Fracanzani AL.

Liver Int. 2019 Dec;39(12):2309-2316. doi: 10.1111/liv.14213. Epub 2019 Aug 30.

PMID:
31419372
7.

Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review.

Lombardi R, Fargion S, Fracanzani AL.

Dig Liver Dis. 2019 Sep;51(9):1214-1222. doi: 10.1016/j.dld.2019.05.015. Epub 2019 Jun 6.

PMID:
31176631
8.

PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Dongiovanni P, Meroni M, Baselli G, Mancina RM, Ruscica M, Longo M, Rametta R, Cespiati A, Pelusi S, Ferri N, Ranzani V, Nobili V, Pihlajamaki J, Fracanzani AL, Badiali S, Petta S, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Lipid Res. 2019 Jun;60(6):1144-1153. doi: 10.1194/jlr.P090449. Epub 2019 Mar 27.

PMID:
30918065
9.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

10.

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.

Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, Dongiovanni P, Fracanzani AL, Badiali S, Maggioni M, Craxi A, Fargion S, Prati D, Nobili V, Bugianesi E, Romeo S, Pihlajamaki J, Petta S, Valenti L.

Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6. doi: 10.1016/j.cgh.2019.01.027. Epub 2019 Jan 29.

PMID:
30708111
11.

Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease.

Tosetti G, Primignani M, La Mura V, D'Ambrosio R, Degasperi E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P.

Dig Liver Dis. 2019 Aug;51(8):1135-1140. doi: 10.1016/j.dld.2018.12.025. Epub 2019 Jan 11.

PMID:
30691777
12.

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.

Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL.

Int J Mol Sci. 2018 Dec 10;19(12). pii: E3966. doi: 10.3390/ijms19123966. Review.

13.

FibroScan Detects Cardiovascular Damage in Patients With NAFLD.

Lombardi R, Petta S, Pisano G, Dongiovanni P, Rinaldi L, Adinolfi LE, Acierno C, Valenti L, Boemi R, Spatola F, Craxì A, Fargion S, Fracanzani AL.

Clin Gastroenterol Hepatol. 2018 Dec 8. pii: S1542-3565(18)31254-0. doi: 10.1016/j.cgh.2018.11.011. [Epub ahead of print]

PMID:
30528844
14.

A sweet fever.

Tiraboschi S, Marzano AV, Lombardi R, Genovese G, Boccoli G, Fargion S, Fracanzani AL.

Intern Emerg Med. 2019 Oct;14(7):1125-1128. doi: 10.1007/s11739-018-1975-y. Epub 2018 Nov 8. No abstract available.

PMID:
30406876
15.

Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis.

Pelusi S, Iuculano F, Lombardi R, Francione P, Gianelli U, Fracanzani AL, Fargion S.

Intern Emerg Med. 2019 Aug;14(5):763-766. doi: 10.1007/s11739-018-1947-2. Epub 2018 Sep 14. No abstract available.

PMID:
30218421
16.

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease.

Dongiovanni P, Meroni M, Mancina RM, Baselli G, Rametta R, Pelusi S, Männistö V, Fracanzani AL, Badiali S, Miele L, Grimaudo S, Petta S, Bugianesi E, Soardo G, Fargion S, Pihlajamäki J, Romeo S, Valenti L.

Hepatol Commun. 2018 Apr 25;2(6):666-675. doi: 10.1002/hep4.1192. eCollection 2018 Jun.

17.

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.

Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M.

Eur J Intern Med. 2018 Jun;52:e12-e14. doi: 10.1016/j.ejim.2018.04.006. Epub 2018 Apr 12. No abstract available.

PMID:
29657108
18.

Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.

Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A.

J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.

PMID:
29505844
19.

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver.

Dongiovanni P, Stender S, Pietrelli A, Mancina RM, Cespiati A, Petta S, Pelusi S, Pingitore P, Badiali S, Maggioni M, Mannisto V, Grimaudo S, Pipitone RM, Pihlajamaki J, Craxi A, Taube M, Carlsson LMS, Fargion S, Romeo S, Kozlitina J, Valenti L.

J Intern Med. 2018 Apr;283(4):356-370. doi: 10.1111/joim.12719. Epub 2017 Dec 27.

20.

Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis.

Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, Biondetti P, Fargion S, Fracanzani AL.

Atherosclerosis. 2018 Jan;268:27-31. doi: 10.1016/j.atherosclerosis.2017.11.012. Epub 2017 Nov 16.

PMID:
29175651
21.

Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease.

Pigoni A, Iuculano F, Saetti C, Airaghi L, Burdick L, Spreafico S, Curioni M, Lombardi R, Valenti L, Fracanzani AL, Fargion S.

Metab Brain Dis. 2018 Feb;33(1):347-352. doi: 10.1007/s11011-017-0107-0. Epub 2017 Sep 16.

PMID:
28918510
22.

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.

Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL.

Eur J Prev Cardiol. 2017 Nov;24(17):1870-1877. doi: 10.1177/2047487317724342. Epub 2017 Jul 31.

PMID:
28758421
23.

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.

Petta S, Valenti L, Tuttolomondo A, Dongiovanni P, Pipitone RM, Cammà C, Cabibi D, Di Marco V, Fracanzani AL, Badiali S, Nobili V, Fargion S, Grimaudo S, Craxì A.

Hepatology. 2017 Dec;66(6):1885-1893. doi: 10.1002/hep.29395. Epub 2017 Nov 6.

PMID:
28741298
24.

Hepatic iron is the major determinant of serum ferritin in NAFLD patients.

Ryan JD, Armitage AE, Cobbold JF, Banerjee R, Borsani O, Dongiovanni P, Neubauer S, Morovat R, Wang LM, Pasricha SR, Fargion S, Collier J, Barnes E, Drakesmith H, Valenti L, Pavlides M.

Liver Int. 2018 Jan;38(1):164-173. doi: 10.1111/liv.13513. Epub 2017 Jul 29.

PMID:
28679028
25.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

26.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

27.

Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S.

Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26.

PMID:
28554682
28.

Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, Dongiovanni P, Rychlicki C, Ferri N, Cammà C, Fracanzani AL, Pierantonelli I, Di Marco V, Meroni M, Giordano D, Grimaudo S, Maggioni M, Cabibi D, Fargion S, Craxì A.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669. doi: 10.1210/jc.2017-00056.

PMID:
28472477
29.

Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.

Dongiovanni P, Meroni M, Baselli GA, Bassani GA, Rametta R, Pietrelli A, Maggioni M, Facciotti F, Trunzo V, Badiali S, Fargion S, Gatti S, Valenti L.

Clin Sci (Lond). 2017 Jun 7;131(12):1301-1315. doi: 10.1042/CS20170175. Print 2017 Jun 1.

PMID:
28468951
30.

GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors.

Greni F, Valenti L, Mariani R, Pelloni I, Rametta R, Busti F, Ravasi G, Girelli D, Fargion S, Galimberti S, Piperno A, Pelucchi S.

Ann Hepatol. 2017 May - Jun;16(3):451-456. doi: 10.5604/16652681.1235489.

31.

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.

Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, Tozzi G, Pujatti PL, Labbadia G, Corazza GR, Averna M, Perticone F, Croce G, Persico M, Bucci T, Baratta F, Polimeni L, Del Ben M, Violi F; LAL-Cirrhosis Collaborative Research Group.

Atherosclerosis. 2017 Jul;262:179-184. doi: 10.1016/j.atherosclerosis.2017.03.038. Epub 2017 Mar 31.

PMID:
28396038
32.

Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis.

Pelusi S, Lombardi R, Airaghi L, Burdick L, Rango M, Penatti A, Fargion S.

J Res Med Sci. 2016 Nov 7;21:117. doi: 10.4103/1735-1995.193508. eCollection 2016.

33.

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study.

Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A.

Liver Int. 2017 Sep;37(9):1389-1396. doi: 10.1111/liv.13397. Epub 2017 Mar 13.

34.

GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors.

Greni F, Valenti L, Mariani R, Pelloni I, Rametta R, Busti F, Ravasi G, Girelli D, Fargion S, Galimberti S, Piperno A, Pelucchi S.

Ann Hepatol. 2017 May - Jun;16(3):451-456. doi: 10.5604/01.3001.0009.8601.

35.

Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study.

Pisano G, Fracanzani AL, Caccamo L, Donato MF, Fargion S.

World J Gastroenterol. 2016 Oct 28;22(40):8869-8882. Review.

36.

Procoagulant imbalance in patients with non-alcoholic fatty liver disease.

Tripodi A, Fracanzani AL, Chantarangkul V, Primignani M, Fargion S.

J Hepatol. 2017 Jan;66(1):248-250. doi: 10.1016/j.jhep.2016.09.025. Epub 2016 Oct 18. No abstract available.

PMID:
27769731
37.

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease.

Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L.

PLoS One. 2016 Sep 20;11(9):e0163069. doi: 10.1371/journal.pone.0163069. eCollection 2016.

38.

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.

Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S.

PLoS One. 2016 Sep 14;11(9):e0162473. doi: 10.1371/journal.pone.0162473. eCollection 2016.

39.

Food quality, effects on health and sustainability today: a model case report.

Borroni VN, Fargion S, Mazzocchi A, Giachetti M, Lanzarini A, Dall'Asta M, Scazzina F, Agostoni C.

Int J Food Sci Nutr. 2017 Feb;68(1):117-120. doi: 10.1080/09637486.2016.1221385. Epub 2016 Aug 31.

PMID:
27580817
40.

GNPAT p.D519G variant and iron metabolism during oral iron tolerance test.

Rametta R, Dongiovanni P, Fargion S, Valenti L.

Hepatology. 2017 Jan;65(1):384-385. doi: 10.1002/hep.28745. Epub 2016 Aug 24. No abstract available.

PMID:
27481658
41.

Liver fat accumulation is associated with circulating PCSK9.

Ruscica M, Ferri N, Macchi C, Meroni M, Lanti C, Ricci C, Maggioni M, Fracanzani AL, Badiali S, Fargion S, Magni P, Valenti L, Dongiovanni P.

Ann Med. 2016 Aug;48(5):384-91. doi: 10.1080/07853890.2016.1188328. Epub 2016 May 25.

PMID:
27222915
42.

Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD.

Lombardi R, Pisano G, Fargion S.

Int J Mol Sci. 2016 Apr 12;17(4):548. doi: 10.3390/ijms17040548. Review.

43.

Hepcidin resistance in dysmetabolic iron overload.

Rametta R, Dongiovanni P, Pelusi S, Francione P, Iuculano F, Borroni V, Fatta E, Castagna A, Girelli D, Fargion S, Valenti L.

Liver Int. 2016 Oct;36(10):1540-8. doi: 10.1111/liv.13124. Epub 2016 Apr 6.

PMID:
26998752
44.

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, Rametta R, Borén J, Montalcini T, Pujia A, Wiklund O, Hindy G, Spagnuolo R, Motta BM, Pipitone RM, Craxì A, Fargion S, Nobili V, Käkelä P, Kärjä V, Männistö V, Pihlajamäki J, Reilly DF, Castro-Perez J, Kozlitina J, Valenti L, Romeo S.

Gastroenterology. 2016 May;150(5):1219-1230.e6. doi: 10.1053/j.gastro.2016.01.032. Epub 2016 Feb 2.

45.

Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.

Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata D, Valenti L, Grigore L, Porzio M, Catapano A, Fargion S.

Atherosclerosis. 2016 Mar;246:208-13. doi: 10.1016/j.atherosclerosis.2016.01.016. Epub 2016 Jan 12.

PMID:
26803429
46.

Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population.

Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, Norata GD, Catapano AL.

Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):141-53. doi: 10.1016/j.numecd.2015.10.013. Epub 2015 Nov 2.

PMID:
26777475
47.

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.

Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L.

Hepatology. 2016 Mar;63(3):787-98. doi: 10.1002/hep.28370. Epub 2016 Jan 14.

PMID:
26605757
48.

MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease.

Petta S, Valenti L, Marra F, Grimaudo S, Tripodo C, Bugianesi E, Cammà C, Cappon A, Di Marco V, Di Maira G, Dongiovanni P, Rametta R, Gulino A, Mozzi E, Orlando E, Maggioni M, Pipitone RM, Fargion S, Craxì A.

J Hepatol. 2016 Mar;64(3):682-90. doi: 10.1016/j.jhep.2015.10.016. Epub 2015 Oct 24.

49.

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection.

Burza MA, Motta BM, Mancina RM, Pingitore P, Pirazzi C, Lepore SM, Spagnuolo R, Doldo P, Russo C, Lazzaro V, Fischer J, Berg T, Aghemo A, Cheroni C, De Francesco R, Fargion S, Colombo M, Datz C, Stickel F, Valenti L, Romeo S.

Hepatology. 2016 Feb;63(2):418-27. doi: 10.1002/hep.28322. Epub 2015 Dec 18.

50.

Increased circulating adiponectin in males with chronic HCV hepatitis.

Canavesi E, Porzio M, Ruscica M, Rametta R, Macchi C, Pelusi S, Fracanzani AL, Dongiovanni P, Fargion S, Magni P, Valenti L.

Eur J Intern Med. 2015 Oct;26(8):635-9. doi: 10.1016/j.ejim.2015.08.001. Epub 2015 Aug 17.

PMID:
26293833

Supplemental Content

Loading ...
Support Center